Skip to content

Application of high field-strength 7.0 T magnetic resonance in the diagnosis, therapeutic strategies and prognosis of 3.0T magnetic resonance negative functional pituitary microadenoma patients

Application of high field-strength 7.0 T magnetic resonance in the diagnosis, therapeutic strategies and prognosis of 3.0T magnetic resonance negative functional pituitary microadenoma patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016618
Enrollment
Unknown
Registered
2018-06-12
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

functional pituitary microadenoma

Interventions

Gold Standard:Pathological examination
Index test:1.5T / 3.0T MRI

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) aged 18-60 years old; (2) clinically and biochemically proven functional pituitary microadenoma; (3) proposed pituitary tumor surgery patients; (4) 1.5T / 3.0T MRI was not detected the pituitary lesions; (5) patients without history of pituitary surgery; (6) the patient agrees to participate in this experiment, and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) do not meet the diagnosis of functional pituitary microadenoma; (2) Incomplete medical records; (3) can not accept follow-up; (4) pregnant or lactating women; (5) using other drugs and / or alcohol abuse; (6) serious respiratory depression (lung), airway obstruction; (7); heart disease (i.e., above grade II and grade II cardiac function); (8) blood system diseases; (9) brain disease patients with impaired judging ability; (10) Contraindication to MRI such as pacemaker, other MR-incompatible metal implants or claustrophobia; (11) Contra-indications for gadolinium; (12) any previous history of severe allergic reactions.

Design outcomes

Primary

MeasureTime frame
Detection rate of pituitary lesions;

Secondary

MeasureTime frame
Interobserver agreement;Intraoperative pituitary tumors;Pathology outcome;symptom status after surgery;Postoperative magnetic resonance;Pituitary hormone;

Countries

China

Contacts

Public ContactMing Feng

Peking Union Medical College Hospital

jackietz@163.com+86 010-69152532

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026